Abstract: The invention relates to methods for coating nanoparticles with a limited amount of a binding partner and nanoparticles obtainable by the methods disclosed. In particular, the invention is of interest, when coating with only a limited amount of protein is desirable.

Abstract: The invention relates to methods for coating nanoparticles with a limited amount of a binding partner and nanoparticles obtainable by the methods disclosed. In particular, the invention is of interest, when coating with only a limited amount of protein is desirable.

Abstract: The present invention relates to methods and kits for the diagnosis and confirmation of Chronic Fatigue Syndrome (CFS) by measuring elastase activity in a patient sample, preferably a PBMC sample. The assays of the invention can also be used to characterize CFS, to determine the disease stage, the disease progression, the efficiency of a therapeutic regime and/or to predict the recurrence of possible attacks. The assays of the invention advantageously allow CFS to be distinguished from other CICIDs like MS or RA.

Abstract: Methods for treating a host suffering from a chronic immune disease, e.g., MS or CFS, are provided. In practicing the subject methods, an effective amount of an elastase inhibitory agent, e.g., a ?-lactam containing compound, is administered to the host. Also provided are compositions for use in practicing the subject methods.

Abstract: Stable metal/conductive polymer composite colloids and methods for making the same are provided. The subject colloids find use in a variety of different applications, including analyte detection applications. Also provided are kits that include the subject colloids.

Abstract: Methods are provided for diagnosing and/or characterizing disease involving abnormal levels of cellular apoptosis activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a disease involving abnormal levels of cellular apoptosis. The sample is then assayed for the presence of low molecular weight Actin protein fragments. The assay results are used to diagnose the presence of disease involving abnormal levels of cellular apoptosis activity and/or characterize disease involving abnormal levels of cellular apoptosis activity in the subject, e.g. to confirm an initial disease involving abnormal levels of cellular apoptosis diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. Also provided by the subject invention are kits for practicing the methods.

Abstract: Stable metal/conductive polymer composite colloids and methods for making the same are provided. The subject colloids find use in a variety of different applications, including analyte detection applications. Also provided are kits that include the subject colloids.

Abstract: Stable metal/conductive polymer composite colloids and methods for making the same are provided. The subject colloids find use in a variety of different applications, including analyte detection applications. Also provided are kits that include the subject colloids.

Abstract: Stable metal/conductive polymer composite colloids and methods for making the same are provided. The subject colloids find use in a variety of different applications, including analyte detection applications. Also provided are kits that include the subject colloids.

Abstract: Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of native Stat-1 protein and/or any lower molecular weight fragments of Stat-1 protein present. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g., to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. In certain embodiments, the assay results are also used to predict the effectiveness of a particularly treatment protocol, e.g., to determine whether an interferon based treatment protocol will be effective. In addition, methods of Stat-1 based methods of treating chronic immune disease conditions are provided.

Abstract: Silicon-containing compounds having selective COX-2 inhibitory activity, as well as compositions thereof are provided. The subject compounds find use in a variety of applications, including therapeutic applications. Also provided are kits containing the subject compounds and pharmaceutical preparations thereof.

Abstract: Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of native Stat-1 protein and/or any lower molecular weight fragments of Stat-1 protein present. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g., to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. In certain embodiments, the assay results are also used to predict the effectiveness of a particularly treatment protocol, e.g., to determine whether an interferon based treatment protocol will be effective. In addition, methods of Stat-1 based methods of treating chronic immune disease conditions are provided.

Abstract: Silicon-containing compounds having selective COX-2 inhibitory activity, as well as compositions thereof are provided. The subject compounds find use in a variety of applications, including therapeutic applications. Also provided are kits containing the subject compounds and pharmaceutical preparations thereof.

Abstract: Methods using colloidal conductive polymers, noble metal nanoparticles or of stable metal/conductive polymer composite colloids as reagents for at least the in vitro prediction of, if not the determination of, PK/ADME-tox properties of new chemical entities (NCEs) are provided. Also provided are kits that include the subject methods and reagents for application thereof. The salient characteristics of these methods and reagents pertaining to the present invention reside in the fact that the reactions in which they are involved are homogeneous, rapid, and proceed as “mix and read” processes.

Abstract: Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of low molecular actin fragments. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g. to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. Also provided by the subject invention are kits for practicing the methods.

Abstract: The present invention relates to methods and kits for the diagnosis and confirmation of Chronic Fatigue Syndrome (CFS) by measuring elastase activity in a patient sample, preferably a PBMC sample. The assays of the invention can also be used to characterize CFS, to determine the disease stage, the disease progression, the efficiency of a therapeutic regime and/or to predict the recurrence of possible attacks. The assays of the invention advantageously allow CFS to be distinguished from other CICIDs like MS or RA.

Abstract: Stable metal/conductive polymer composite colloids and methods for making the same are provided. The subject colloids find use in a variety of different applications, including analyte detection applications. Also provided are kits that include the subject colloids.

Abstract: Silicon-containing compounds having selective COX-2 inhibitory activity, as well as compositions thereof are provided. The subject compounds find use in a variety of applications, including therapeutic applications. Also provided are kits containing the subject compounds and pharmaceutical preparations thereof.

Abstract: Methods are provided for diagnosing/characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence and amount of intact (i.e., native) p53 protein and/or fragments thereof. The assay results are used to diagnose the presence of chronic immune disease and/or characterize chronic immune disease activity in a subject, and/or to determine appropriate treatments protocols. Also provided by the subject invention are methods of treating chronic immune disease conditions by enhancing p53 activity. Also provided by the subject invention are kits for practicing the methods.

Abstract: Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of low molecular actin fragments. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g. to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. Also provided by the subject invention are kits for practicing the methods.